{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:06:07Z","timestamp":1790723167767,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Premenopausal women with triple-negative breast cancer (TNBC) exhibit considerable heterogeneity in their response to standard anthracycline and taxane-based chemotherapy, yet the underlying mechanisms remain poorly understood. We aimed to investigate the combined role of the tumour immune microenvironment and HER2-low status in predicting chemosensitivity and intrinsic resistance in this specific population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed data from 767 premenopausal patients with TNBC across two Chinese medical centres. All patients underwent primary surgery followed by adjuvant chemotherapy based on anthracyclines and taxanes. Patients were randomly assigned to training and internal validation cohorts. Independent predictors of DFS were identified using multivariable Cox proportional hazards regression, and a nomogram was constructed accordingly. The model\u2019s discrimination was assessed using the concordance index (C-index) and time-dependent receiver operating characteristic (ROC) curve analysis, while calibration was evaluated with calibration curves.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Multivariable analysis identified lower stromal tumour-infiltrating lymphocyte (sTIL) expression levels, and HER2 IHC 2+\/FISH-negative status as independent factors associated with poorer DFS, besides that T3\/T4 staging, higher N staging. A nomogram integrating these four variables demonstrated excellent predictive accuracy for DFS, with a C-index of 0.862 in the training set and 0.861 in the validation set. The area under the ROC curve (AUC) for predicting 3-year DFS was 0.907 and 0.908 in the training and validation sets, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings reveal that an immune-poor tumour microenvironment and HER2-low biology are key, complementary determinants of intrinsic resistance to standard chemotherapy in premenopausal TNBC. These readily available biomarkers provide a mechanistic rationale for patient stratification, suggesting that sTIL-low tumours might benefit from immunomodulatory strategies, while HER2-low tumours represent a candidate population for novel antibody-drug conjugates. This paradigm shift from empirical to biomarker-informed therapy could help overcome chemoresistance in this high-risk group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1752328","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T07:29:39Z","timestamp":1770622179000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumour microenvironment and HER2-low status dictate response and resistance to anthracycline-taxane chemotherapy in premenopausal TNBC: a retrospective multicohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Shuanglong","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Comprehensive Breast Health Center, The First Affiliated Hospital of Lishui University, Lishui People\u2019s Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohong","family":"Yu","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Kuang","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Comprehensive Breast Health Center, The First Affiliated Hospital of Lishui University, Lishui People\u2019s Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Comprehensive Breast Health Center, The First Affiliated Hospital of Lishui University, Lishui People\u2019s Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Comprehensive Breast Health Center, The First Affiliated Hospital of Lishui University, Lishui People\u2019s Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuzhou University Affiliated Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital","place":["Fuzhou, Fujian, China"]},{"name":"Fujian Provincial Key Laboratory of Cardiovascular Disease, Fujian Cardiovascular Institute, Fujian Provincial Center for Geriatrics, Fujian Clinical Medical Research Center for Cardiovascular Diseases","place":["Fuzhou, Fujian, China"]},{"name":"Fujian Heart Failure Center Alliance","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Comprehensive Breast Health Center, The First Affiliated Hospital of Lishui University, Lishui People\u2019s Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Comprehensive Breast Health Center, The First Affiliated Hospital of Lishui University, Lishui People\u2019s Hospital","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamaoncol.2018.7147","article-title":"Current landscape of immunotherapy in breast cancer: a review","volume":"5","author":"Adams","year":"2019","journal-title":"JAMA Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3390\/cancers13112824","article-title":"HER2-Low breast cancer: molecular characteristics and prognosis","volume":"13","author":"Agostinetto","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-11-2599","article-title":"Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling","volume":"18","author":"Azim","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/annonc\/mdy024","article-title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","volume":"29","author":"Bareche","year":"2018","journal-title":"Ann. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","article-title":"Comprehensive molecular portraits of invasive lobular breast cancer","volume":"163","author":"Ciriello","year":"2015","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1002\/cncr.23843","article-title":"Guideline implementation for breast healthcare in low- and middle-income countries: treatment resource allocation","volume":"113","author":"Eniu","year":"2008","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","article-title":"Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer","volume":"17","author":"Gonzalez-Angulo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1-or BRCA2-Mutated breast cancer","volume":"384","author":"J Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.semcancer.2018.07.001","article-title":"Scoring of tumor-infiltrating lymphocytes: from visual estimation to machine learning","volume":"52","author":"Klauschen","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/jamaoncol.2024.1917","article-title":"Tumor-Infiltrating lymphocytes in patients with stage I triple-negative breast cancer untreated with chemotherapy","volume":"10","author":"M Geurts","year":"2024","journal-title":"JAMA Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"104087","DOI":"10.1016\/j.esmoop.2024.104087","article-title":"Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study","volume":"10","author":"Miglietta","year":"2025","journal-title":"ESMO Open"},{"key":"B27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1038\/s41591-025-03981-4","article-title":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","volume":"31","author":"Modi","year":"2025","journal-title":"Nat. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"11479","DOI":"10.1038\/ncomms11479","article-title":"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat. Commun."},{"key":"B32","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann. Oncol."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.11.007","article-title":"Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03","volume":"17","author":"Saura","year":"2025","journal-title":"Ann. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"102865","DOI":"10.1016\/j.ctrv.2024.102865","article-title":"Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: a systematic review and network meta-analysis","volume":"132","author":"Schettini","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-Gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-Low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of hereditary breast cancer: American Society of clinical oncology, American Society for radiation oncology, and Society of Surgical Oncology Guideline","volume":"38","author":"Tung","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/s43018-022-00416-8","article-title":"Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer","volume":"3","author":"Vanguri","year":"2022","journal-title":"Nat. Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"106","DOI":"10.7497\/j.issn.2095-3941.2015.0030","article-title":"Current approaches in treatment of triple-negative breast cancer","volume":"12","author":"Wahba","year":"2015","journal-title":"Cancer Biol. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2020.23370","article-title":"Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial","volume":"325","author":"Wang","year":"2021","journal-title":"JAMA"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple-negative breast cancer therapy: current and future perspectives","volume":"57","author":"Won","year":"2020","journal-title":"Int. J. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1752328\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:54:57Z","timestamp":1771926897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1752328\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":48,"alternative-id":["10.3389\/fphar.2026.1752328"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1752328","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"article-number":"1752328"}}